Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Reports Q1 2024 Financial Results and Pipeline Updates
Summary
Terns Pharmaceuticals, Inc. reported its financial results for the first quarter of 2024, highlighting its cash position and progress in clinical trials for its pipeline of small molecule therapies. The company expects to report interim data from its Phase 1 CARDINAL trial of TERN-701 in CML and top-line data from the Phase 1 trial of TERN-601 in obesity in the second half of 2024. Terns also provided updates on its pipeline, including the FDA Orphan Drug Designation for TERN-701 and the appointment of Melita Sun Jung as chief business officer.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement